Interview with Rubens Lima, General Manager, Ipsen Brazil
In a past interview, you said that Ipsen is different than the “Big Pharmas” who have entered Brazil by acquisition. You’ve taken a different tack since arriving as one of…
Address: Av. Luis Carlos Berrini, 1297 cj 61 – Cidade Monções São Paulo – SP – CEP: 04571-010 Brasil,Brazil
Tel: -5693
Web: http://www.ipsen.com/en/ipsen-worldwide
Ipsen is a group that operates in the global biotechnology and pharmaceutical innovation in medical specialties with more than 20 in the world market. The Ipsen Group has a worldwide staff of about 4,000 employees. Its development strategy is based on a combination of special medicines in several therapeutic areas (oncology, endocrinology, neurology and hematology) and primary care products. The company has four R & D centers (Paris, Boston, Barcelona and London) and has a group of highly qualified researchers. More than 900 people in R & D are dedicated to the discovery of innovative medicines. This strategy is also supported by an active policy of partnerships of the Ipsen Group.
In 2010, total revenue was € 1.1 billion (USD $ 1.6 billion). Ipsen invested approximately € 220 million (USD $ 315 million, or 20% of consolidated sales) on research and development (a larger percentage of the global pharmaceutical industry). Ipsen has an extensive and sophisticated R & D program, which includes about 20 lines of research, from preclinical to Phase III.
The company’s clinical trials in Brazil are conducted in partnership with major research centers like the University of São Paulo (USP), Federal University of Rio de Janeiro (UFRJ), Universidade de Brasília (UnB) and Catholic University of Porto Alegre.
Dysport ® (Botulinum toxin type A, 500U, for the treatment of dystonias, spasticity and cosmetic uses), Somatuline ® Autogel ® (lanreotide for the treatment of acromegaly and neuroendocrine tumors), Apokyn ® (apomorphine for the treatment of the syndrome. advanced Parkinson’s), Nutropin ® (growth hormone) and INCRELEX ® (IGF-1 for the treatment of growth deficits).
In a past interview, you said that Ipsen is different than the “Big Pharmas” who have entered Brazil by acquisition. You’ve taken a different tack since arriving as one of…
Novo Nordisk’s Latin America lead Allan Finkel outlines the “alarming” burden of diabetes and obesity in his region, the progress that has been made via national campaigns against diabetes, and…
GSK’s head of Emerging Markets, Luis Arosemena, comments on the strategic importance of this wide-ranging country grouping for the company, the structure of his organisation in Latin America, the importance…
The latest from Brazilian Pharma, including the approval of home grown cannabis for medical use, Cellera Farma’s partnership with Ferring, a considerable increase in demand for oncology drugs, and a…
The latest from the healthcare industry in Latin America, including an alarming OECD report about the decline of well-being in the region due to Covid-19, Bayer’s USD 350 million investment…
The latest news from Brazil, including Pfizer’s plans to vaccinate the entire Brazilian city of Toledo, what the US can learn from Brazil’s successful vaccine campaign, and a new deal…
The latest news from Brazilian pharma, including an investigation into the country’s deal with Indian lab Bharat Biotech to purchase COVID-19 vaccines; the IP and regulatory challenges around personalised medicine…
Founded in 1950, EMS is one of the top two domestic pharma companies in Brazil. As a key player in the largest and most populous nation in Latin America, the…
The Brazilian pharma market outperformed the Latin American average in Q1 of 2020 with a growth of 8.2 percent in real terms (inflation adjusted), according to IQVIA. Its size reached…
Six of the top ten companies in the Brazilian pharma market are domestic.* Read on for an introduction to some of the Brazilian giants that are perhaps less well known…
Panorama Faramceutico’s editorial team look at how the ongoing COVID-19 pandemic stands to affect Brazil’s over the counter (OTC) market segment during and after the COVID-19 pandemic.* The OTC…
In the race to develop the world’s first COVID-19 vaccine, Brazil – now one of the world’s worst-affected countries – is becoming an attractive clinical trial destination for biopharma companies…
The editorial team at Panorama Farmaceutico explain how the COVID-19 pandemic and global trade flow stoppages are impacting the manufacture and supply of medicines within Brazil.* The COVID-19 pandemic…
See our Cookie Privacy Policy Here
